GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Explainer] why an oral non-peptide escapes the absorption problem entirely — 46 comments in the full submission. View in context.
1.3k
c/glp1science·submitted 26 days ago by u/fatima_kowalski

[Explainer] why an oral non-peptide escapes the absorption problem entirely

Explainerbranch of 7 comments

Something I noticed reading old threads that I have not seen said out loud. The advice on gastric emptying in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory…

Read the full submission and all 46 comments →

This branch

7 comments, started 25 days ago
u/camila_lindqvist57 points·25 days ago

Strongly agree. Central appetite is real but people overstate it.

replysharereportpermalink
u/laila_almeida14 points·25 days ago

Strongly agree. Central appetite is real but people overstate it.

replysharereportpermalink
u/camila_lindqvist6 points·24 days ago

central appetite signalling is real but people overweight it

replysharereportpermalink
u/tomas_broberg27 points·24 days ago

Strongly agree.

Disagree on that part. 99.2% and 99.3% on the same vial is normal.

replysharereportpermalink
u/sig_figs_sammod · analytical47 points·24 days ago·edited

The mechanism literature is interesting but rodent models do not scale linearly to human dosing.

replysharereportpermalink
u/ismael_eriksen15 points·24 days ago·edited

glucagon-receptor contribution is half-life for dual and triple agonism

replysharereportpermalink
u/signe_boateng0 points·24 days ago

do not extrapolate rodent data to human dosing without saying so

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →